The level of IL-17A expression was found to be higher in cervical tumor samples, 81–100 years of age, African American patients, obese and extremely obese patients, cancer stage 1 and stage 2, and in patients with tumor grade 2 and grade 3. This evidence concerns the gene IL17A and uterine cervix neoplasm.